Furthermore, the modulation of Abl overexpression, amplification, and mutation is a causative factor in solid tumors, and hence, there is a pressing need to direct drug discovery efforts to develop small molecule inhibitors of Abl kinases for cancer therapy. The gene discussed is ABL1; the disease is cancer.